TARA Biosystems Company

Tara Biosystems provides predictive, in vitro human cardiac tissue models for use in drug discovery, safety assessment and translational medicine. Tara Biosystems offers a high-fidelity solution that is based on human stem cell-derived cardiac tissue matured to physiologically relevant adult-like levels and provides direct measures of cardiac functionality, including contractile force. The company is dedicated to pioneering predictive cardiac tissue models that enable the faster, safer, and more reliable development of new medicines.
Technology: Biotechnology, Medical
Industry: Early Drug Development
Headquarters: New York, New York, United States
Founded Date: 2014-01-01
Employees Number: 11-50
Funding Status: Early Stage Venture
Investors Number: 11
Total Funding: 21250000
Estimated Revenue: Less than $1M
Last Funding Date: 2020-06-23
Last Funding Type: Series A

Visit Website
Register and Claim Ownership